Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas

por Loni, L, Tacca, M Del, Danesi, R
Publicado 2001

Imatinib administration in two patients with liver metastases from GIST and severe jaundice

por De Pas, T, Danesi, R, Catania, C, Curigliano, G, de Braud, F
Publicado 2003

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile

por Giovannetti, E, Mey, V, Danesi, R, Basolo, F, Barachini, S, Deri, M, Del Tacca, M
Publicado 2005

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

por Bocci, G, Fioravanti, A, Orlandi, P, Bernardini, N, Collecchi, P, Del Tacca, M, Danesi, R
Publicado 2005

Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation.

por Bernardini, N., Giannessi, F., Bianchi, F., Dolfi, A., Lupetti, M., Citti, L., Danesi, R., Del Tacca, M.
Publicado 1993

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells

por Paolo, A Di, Danesi, R, Caputo, S, Macchia, M, Lastella, M, Boggi, U, Mosca, F, Marchetti, A, Tacca, M Del
Publicado 2001

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

por Danesi, R., Del Bianchi, S., Soldani, P., Campagni, A., La Rocca, R. V., Myers, C. E., Paparelli, A., Del Tacca, M.
Publicado 1993

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells

por Paolo, A Di, Danesi, R, Nardini, D, Bocci, G, Innocenti, F, Fogli, S, Barachini, S, Marchetti, A, Bevilacqua, G, Tacca, M Del
Publicado 2000

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

por Mey, V, Giovannetti, E, Braud, F De, Nannizzi, S, Curigliano, G, Verweij, F, De Cobelli, O, Pece, S, Del Tacca, M, Danesi, R
Publicado 2006

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

por Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.
Publicado 2021

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards

por Danesi, R., Fogli, S., Indraccolo, S., Del Re, M., Dei Tos, A.P., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., Amunni, G., Conte, P.
Publicado 2021

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

por Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Publicado 2008

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

por Allegrini, G, Falcone, A, Fioravanti, A, Barletta, M T, Orlandi, P, Loupakis, F, Cerri, E, Masi, G, Di Paolo, A, Kerbel, R S, Danesi, R, Del Tacca, M, Bocci, G
Publicado 2008

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

por Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Publicado 2013

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

por Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U., Danesi, R.
Publicado 2021

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

por Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U., Danesi, R.
Publicado 2022

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

por Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Publicado 2011

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

por Conte, P., Ascierto, P.A., Patelli, G., Danesi, R., Vanzulli, A., Sandomenico, F., Tarsia, P., Cattelan, A., Comes, A., De Laurentiis, M., Falcone, A., Regge, D., Richeldi, L., Siena, S.
Publicado 2022

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

por Bengala, C, Guarneri, V, Giovannetti, E, Lencioni, M, Fontana, E, Mey, V, Fontana, A, Boggi, U, Del Chiaro, M, Danesi, R, Ricci, S, Mosca, F, Del Tacca, M, Conte, P F
Publicado 2005

Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologi...

por Silvestris, N., Argentiero, A., Natalicchio, A., D'Oronzo, S., Beretta, G.D., Acquati, S., Adinolfi, V., Di Bartolo, P., Danesi, R., Faggiano, A., Ferrari, P., Gallo, M., Gori, S., Morviducci, L., Russo, A., Tuveri, E., Zatelli, M.C., Montagnani, M., Giorgino, F.
Publicado 2021